Category: Dr. Reddy’s
-
Double jeopardy takes down Sanofi’s cabazitaxel use patent as UPC’s Munich LD revokes after EPO BoA affirmance
Lawyers representing generics makers welcomed the UPC’s decision to revoke the patent regardless of a prior EPO decision to the contrary.
-
Delhi High Court allows Dr. Reddy’s to enter Indian semaglutide market in March 2026, dismisses Novo Nordisk appeal
In a landmark judgment, the Delhi High Court has ruled that Novo Nordisk failed to prove why it should be granted an interim injunction against Dr. Reddy’s, but has ordered the latter not to proceed with sales in Indian until the patent-in-suit expires on March 20, 2026.
-
Boehringer wins PI against Dr. Reddy’s that blocks generic empagliflozin (Jardiance) sales in UK pending October 2026 trial: patent thickets work
In some jurisdictions it pays off for Boehringer Ingelheim to have created a patent thicket around empaglifozin (Jardiance) involving use and formulation patents.
